StockMacro
Menu

Utah Medical Products

$69.49 +6.5% in 6 monthsMarket cap $198.0M

UTMD on XNAS, Health Care, Utah Medical Products Inc, job postings

Measures activity, not value. Not investment advice.

Revenue fell 9.6% to $34.9M while institutional holders rose 13% to 127.

  • BadNet income fell 8.4% to $10.6M over the last 12 months
  • GoodFree cash flow of $10.9M and cash of $85.2M, with $180K debt

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
152
Website
utahmed.com
Listed
Nasdaq, US
Last results
22 Oct 2026
Next results
expected around 28 Jan 2027 (an estimate: a year ago it reported on 29 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $8.6M, net income $2.8M.
Quarter to 31 Dec 2021: revenue $12.9M, net income $4.1MQuarter to 31 Dec 2021: revenue $12.9M, net income $4.1MQuarter to 31 Mar 2022: revenue $12.3M, net income $3.5MQuarter to 31 Mar 2022: revenue $12.3M, net income $3.5MQuarter to 30 Jun 2022: revenue $13.4M, net income $4.1MQuarter to 30 Jun 2022: revenue $13.4M, net income $4.1MQuarter to 30 Sep 2022: revenue $13.0M, net income $4.3MQuarter to 30 Sep 2022: revenue $13.0M, net income $4.3MQuarter to 31 Dec 2022: revenue $13.6M, net income $4.6MQuarter to 31 Dec 2022: revenue $13.6M, net income $4.6MQuarter to 31 Mar 2023: revenue $12.5M, net income $4.2MQuarter to 31 Mar 2023: revenue $12.5M, net income $4.2MQuarter to 30 Jun 2023: revenue $12.9M, net income $4.2MQuarter to 30 Jun 2023: revenue $12.9M, net income $4.2MQuarter to 30 Sep 2023: revenue $12.5M, net income $3.9MQuarter to 30 Sep 2023: revenue $12.5M, net income $3.9MQuarter to 31 Dec 2023: revenue $12.3M, net income $4.3MQuarter to 31 Dec 2023: revenue $12.3M, net income $4.3MQuarter to 31 Mar 2024: revenue $11.3M, net income $4.0MQuarter to 31 Mar 2024: revenue $11.3M, net income $4.0MQuarter to 30 Jun 2024: revenue $10.4M, net income $3.5MQuarter to 30 Jun 2024: revenue $10.4M, net income $3.5MQuarter to 30 Sep 2024: revenue $10.0M, net income $3.6MQuarter to 30 Sep 2024: revenue $10.0M, net income $3.6MQuarter to 31 Dec 2024: revenue $9.2M, net income $2.9MQuarter to 31 Dec 2024: revenue $9.2M, net income $2.9MQuarter to 31 Mar 2025: revenue $9.7M, net income $3.0MQuarter to 31 Mar 2025: revenue $9.7M, net income $3.0MQuarter to 30 Jun 2025: revenue $10.0M, net income $3.0MQuarter to 30 Jun 2025: revenue $10.0M, net income $3.0MQuarter to 30 Sep 2025: revenue $9.8M, net income $2.6MQuarter to 30 Sep 2025: revenue $9.8M, net income $2.6MQuarter to 31 Dec 2025: revenue $9.0M, net income $2.6MQuarter to 31 Dec 2025: revenue $9.0M, net income $2.6MQuarter to 31 Mar 2026: revenue $8.7M, net income $2.6MQuarter to 31 Mar 2026: revenue $8.7M, net income $2.6MQuarter to 30 Jun 2026: revenue $8.5M, net income $2.7MQuarter to 30 Jun 2026: revenue $8.5M, net income $2.7MQuarter to 30 Sep 2026: revenue $8.6M, net income $2.8MQuarter to 30 Sep 2026: revenue $8.6M, net income $2.8M
31 Dec 2021RevenueNet incometallest bar $13.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$8.6M$2.8M
30 Jun 2026$8.5M$2.7M
31 Mar 2026$8.7M$2.6M
31 Dec 2025$9.0M$2.6M
30 Sep 2025$9.8M$2.6M
30 Jun 2025$10.0M$3.0M
31 Mar 2025$9.7M$3.0M
31 Dec 2024$9.2M$2.9M
30 Sep 2024$10.0M$3.6M
30 Jun 2024$10.4M$3.5M
31 Mar 2024$11.3M$4.0M
31 Dec 2023$12.3M$4.3M
30 Sep 2023$12.5M$3.9M
30 Jun 2023$12.9M$4.2M
31 Mar 2023$12.5M$4.2M
31 Dec 2022$13.6M$4.6M
30 Sep 2022$13.0M$4.3M
30 Jun 2022$13.4M$4.1M
31 Mar 2022$12.3M$3.5M
31 Dec 2021$12.9M$4.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $34.9M $38.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -9.6% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $10.6M $11.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $3.34 $3.54
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 57.7% 57.1% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 29.9% 30.8% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 30.5% 30.1% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 8.8% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $10.9M $13.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $85.2M $84.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $180K –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$85.0M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.00 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $43.26
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 18.6 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.7 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.2 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.6 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Utah Medical ProductsUTMD (this company) $198.0M18.65.7-9.6%30.5%
Pro-Dex Inc NewPDEX $201.6M16.82.5+13%15.1%
Anika TherapeuticsANIK $177.2Mloss1.4+9.4%-1.4%
ClearPoint NeuroCLPT $221.5Mloss4.9+33%-79.4%
Newegg CommerceNEGG $167.8Mloss0.12+17%-0.3%
Profound MedicalPROF $233.7Mloss9.9+65%-138%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$67K

bought $67K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+13%

127 13F filers vs 112

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

82%

2.3M shares held by 13F filers (30 Sep 2026) of 2.8M outstanding (12 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.3%

151K shares sold short (30 Oct 2026) of 2.8M outstanding (12 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.9

151K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+7.9%

140K shares sold short in the report before, 151K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

57%

57% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 63%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

4 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $69.49 on 20 Nov 2026, +29% over 12 months (12-month range $53.80 to $76.66)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $67K in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $8.6M in the latest quarter, -12% on a year earlier.
Capital spending per quarter. Capital spending $236K in the latest quarter, +774% on a year earlier.
Institutional holders (13F filers). 127 13F filers reported holding it in the latest 13F quarter, +14% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
4 Nov 20258-K and other filingsDirector or officer change
4 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jul 20248-K and other filingsCompleted an acquisition or asset sale
25 Apr 20248-K and other filingsCompleted an acquisition or asset sale
Insider net buying (open market)
Month from 1 Nov 2021: -$632K published
Month from 1 May 2022: -$170K published
Month from 1 Nov 2022: -$59K published
Month from 1 May 2023: -$65K published
Month from 1 Oct 2026: $67K published
Revenue per quarter
Quarter ended 31 Dec 2021: $12.9M, +7.5% on a year earlier; public on 26 Mar 2022
Quarter ended 31 Mar 2022: $12.3M, +12% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $13.4M, +6.5% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $13.0M, +3.0% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $13.6M, +5.1% on a year earlier; public on 28 Mar 2023
Quarter ended 31 Mar 2023: $12.5M, +1.6% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $12.9M, -4.2% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $12.5M, -3.5% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $12.3M, -9.1% on a year earlier; public on 27 Mar 2024
Quarter ended 31 Mar 2024: $11.3M, -9.4% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $10.4M, -19% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $10.0M, -20% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $9.2M, -26% on a year earlier; public on 27 Mar 2025
Quarter ended 31 Mar 2025: $9.7M, -14% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $10.0M, -4.3% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $9.8M, -1.9% on a year earlier; public on 15 Nov 2025
Quarter ended 31 Dec 2025: $9.0M, -1.2% on a year earlier; public on 28 Mar 2026
Quarter ended 31 Mar 2026: $8.7M, -10% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $8.5M, -14% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $8.6M, -12% on a year earlier; public on 14 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $253K, +369% on a year earlier; public on 26 Mar 2022
Quarter ended 31 Mar 2022: $237K, +2270% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $213K, +0.5% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $321K, +317% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $38K, -85% on a year earlier; public on 28 Mar 2023
Quarter ended 31 Mar 2023: $43K, -82% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $320K, +50% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $186K, -42% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $90K, +137% on a year earlier; public on 27 Mar 2024
Quarter ended 31 Mar 2024: $22K, -49% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $110K, -66% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $89K, -52% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $9K, -90% on a year earlier; public on 27 Mar 2025
Quarter ended 31 Mar 2025: $184K, +736% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $51K, -54% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $27K, -70% on a year earlier; public on 15 Nov 2025
Quarter ended 31 Dec 2025: $109K, +1111% on a year earlier; public on 28 Mar 2026
Quarter ended 31 Mar 2026: $130K, -29% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $134K, +163% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $236K, +774% on a year earlier; public on 14 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 73; public on 14 Feb 2022
31 Mar 2022 report: 81; public on 16 May 2022
30 Jun 2022 report: 73; public on 15 Aug 2022
30 Sep 2022 report: 72; public on 14 Nov 2022
31 Dec 2022 report: 75; public on 14 Feb 2023
31 Mar 2023 report: 81; public on 15 May 2023
30 Jun 2023 report: 82; public on 14 Aug 2023
30 Sep 2023 report: 88; public on 14 Nov 2023
31 Dec 2023 report: 85; public on 14 Feb 2024
31 Mar 2024 report: 96; public on 15 May 2024
30 Jun 2024 report: 97; public on 14 Aug 2024
30 Sep 2024 report: 106; public on 14 Nov 2024
31 Dec 2024 report: 112; public on 14 Feb 2025
31 Mar 2025 report: 107; public on 15 May 2025
30 Jun 2025 report: 105; public on 14 Aug 2025
30 Sep 2025 report: 111; public on 14 Nov 2025
31 Dec 2025 report: 113; public on 17 Feb 2026
31 Mar 2026 report: 114; public on 15 May 2026
30 Jun 2026 report: 112; public on 14 Aug 2026
30 Sep 2026 report: 127; public on 16 Nov 2026
Federal obligations
Month from 1 Feb 2024: -$12K published
Month from 1 Jul 2024: -$17K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $67K (29 Oct 2026), higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $67K in the last 12 months (the 12 months before: $0).
  • Revenue per quarter: Revenue $8.6M in the latest quarter, -12% on a year earlier.
  • Capital spending per quarter: Capital spending $236K in the latest quarter, +774% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 62 insider trades

Last 90 days: no sales; 1 purchase, $67K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
29 Oct 2026Kevin L CornwellChairman, CEOBuy1,000$66.75$67KForm 4
19 May 2023Paul O RichinsDirectorSell700$93.47$65KForm 4
21 Nov 2022Paul O RichinsDirectorSell449$90.81$41KForm 4
17 Nov 2022Paul O RichinsDirectorSell161$90.00$14KForm 4
15 Nov 2022Paul O RichinsDirectorSell40$92.50$4KForm 4
11 May 2022Barbara A PayneDirectorSell2,000$85.20$170KForm 4
26 Nov 2021Ernst G HoyerDirectorSell5,000$126.38$632KForm 4
18 Nov 2021Barbara A PayneDirectorSell2,000$111.06$222KForm 4

127 institutions reported shares at the end of Q3 2026, 82% of the shares outstanding; 18 opened a position, 5 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Brandes Investment Partners, LP531K18.6%$39.3M+56K+12%
Dimensional Fund Advisors LP204K7.15%$15.1M+4,955+2.5%
BlackRock, Inc.198K6.93%$14.6M-6,142-3.0%
Renaissance Technologies LLC168K5.88%$12.4M-8,300-4.7%
Vanguard Capital Management LLC137K4.80%$10.1M+2,218+1.6%
Minerva Advisors LLC94K3.29%$6.9MNo change
Geode Capital Management, LLC76K2.68%$5.7M-32K-29%
Rice Hall James & Associates, LLC68K2.37%$5.0M-3,772-5.3%
Hotchkis & Wiley Capital Management LLC65K2.30%$4.8M-20K-23%
State Street Corp65K2.29%$4.9M+1,423+2.2%

Company events

All 9 company events

Nothing in 12 months; the latest was filed 4 Nov 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
4 Nov 2025Director or officer change8-K
5 Nov 2024Director or officer change8-K
25 Jul 2024Completed an acquisition or asset sale8-K
25 Apr 2024Completed an acquisition or asset sale8-K
1 Mar 2021A major agreement ended8-K
12 Feb 2019Completed an acquisition or asset sale8-K
7 Jan 2019Signed a major agreement8-K
16 Nov 2018Changed its auditor8-K

The 5 newest of 40 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 29 Oct 2026Insiders record

    CORNWELL KEVIN L (Chairman, CEO) bought 1,000 shares of UTMD ($66,750)

  2. 4 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 4 Nov 2025Filings record

    Director or officer change

  4. 5 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 5 Nov 2024Filings record

    Director or officer change

  6. 25 Jul 2024Filings record

    Completed an acquisition or asset sale

  7. 25 Apr 2024Filings record

    Completed an acquisition or asset sale

  8. 1 Mar 2021Filings record

    A major agreement ended

  9. 13 Feb 2019Filings record

    Completed an acquisition or asset sale (dated 12 Feb 2019)

  10. 16 Nov 2018Filings record

    Changed its auditor

  11. 2 Apr 2018Filings record

    Director or officer change

Not listed: 163 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000706698
Ticker
UTMD
Domain
utahmed.com
Hq location
UT|MIDVALE|84070 (1 unverified)
Name
Abcorp Medical, Columbia Medical & Surgical, Inc, Femcare Australia Pty Ltd, Femcare Group Limited and 4 more
Uei
KFNCCQTKN2L5
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)110 records2 Feb 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1133 data points31 Dec 2008 to 12 Nov 2026
  • SEC Form 4 insider transactions62 records, 228 data points27 May 2016 to 29 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards390 data points4 Oct 2007 to 25 Jul 2024